INM — InMed Pharmaceuticals Inc.

Summary of InMed Pharmaceuticals Q4 2022 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $18.6 million for the fiscal year ended June 30, 2022, compared to a net loss of $10.2 million in the previous year.
• Loss Per Share: $33.17, down from $37.96 per share year-over-year.
• R&D Expenses: Increased to $7.3 million from $5.3 million, primarily due to the inclusion of BayMedica's results and increased activities related to the INM-755 Phase 2 trial.
• G&A Expenses: Rose by 54% to $6.9 million, attributed to BayMedica's operating results and higher costs associated with being listed on Nasdaq.
• BayMedica Revenue: Generated $1.1 million in sales, reflecting challenges in the rare cannabinoid market.
• Cash Position: $6.2 million as of June 30, 2022, with additional financing of approximately $5.4 million expected to support operations into the second half of fiscal 2023.

2. Strategic Updates and Business Highlights

• Clinical Trials: Progressing with the Phase 2 trial of INM-755 for epidermolysis bullosa (EB), now enrolling adolescents, with a data readout anticipated in Q1 2023.
• INM-088 Development: Preclinical research for glaucoma is advancing, with plans to file an IND application in H1 2024.
• Neurodegenerative Disease Pipeline: Filed a patent for cannabinoid treatments targeting diseases like Alzheimer's and Parkinson's, with ongoing research for potential candidates.
• BayMedica Operations: Focus on launching new products and building a portfolio of rare cannabinoids, although revenue growth has been slower than expected.

3. Forward Guidance and Outlook

• Upcoming Catalysts: Expected completion of the Phase 2 trial for INM-755 and data readout in early 2023, IND-enabling studies for INM-088 by the end of 2023, and candidate selection for neurodegenerative diseases in Q2 2023.
• Cost-Saving Measures: Implemented significant cost reductions, including a 25% workforce reduction and management salary cuts, aiming for a 30% annual savings in human resource expenses.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: The biotech sector is facing severe capital market challenges, particularly for small-cap companies, impacting funding and operational capabilities.
• BayMedica Performance: Revenue growth has been hindered by economic uncertainty and immature market conditions for rare cannabinoids, leading to a strategic reduction in commercial activities.
• Impairment Charges: A non-cash impairment of $3.5 million related to BayMedica's intangible assets and goodwill was recorded due to the refocus on core pharmaceutical development.

5. Notable Q&A Insights

• Efficacy Data from INM-755: No specific efficacy data was reported from the independent data monitoring committee; they only confirmed safety for adolescent enrollment.
• Future Trials: Management anticipates that additional trials will be necessary following the Phase 2 trial for INM-755, as the current study's data may not be sufficient for regulatory filing.
• Burn Rate: The company reported a monthly burn rate of approximately $900,000, expected to decrease to around $700,000, with operational expenses projected at about $500,000 per month.

This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, challenges faced, and insights from the Q&A session during InMed Pharmaceuticals' Q4 2022 earnings call.